Avid Bioservices Inc (CDMO)

[sunstar]

EvaluatePharma is estimating $153+ billion for the 2020 worldwide oncology market.

I would not be surprised if there were Big Pharma/PPHM milestones in place to be tripped, leading to a deal of stellar proportions. I'm thinking the NSCLC early look-ins will tell the tale for an interested pharma. By spring 2015 there should be adequate data to verify the open phase1 melanoma immunotherapy combination of Bavi + Yervoy, as well.

A deal must, will have to be, appropriate to the many maturing clinical benefits of the anti-PS immuno platform. That $153 billion 2020 oncology market, six years away, is about double the current market. This is a massive market, and the analysts have recognized that immunotherapy will dominate the oncology therapies.

Months? Weeks? Something's going to give.

IMO

sunstar